Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT04666038 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04666038
- Sponsor
- Loxo Oncology, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-09
- Primary completion
- 2023-08-29
- Enrollment
- 238
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.